Rigel Pharma (RIGL) Misses Q1 EPS by 2c
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $46.64 +1.72%
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +15.2%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q1 EPS of ($0.05), $0.02 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $29.53 million versus the consensus estimate of $31.48 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
